NVCR - Novocure completes enrollment in late-stage TTFields ovarian cancer study

Novocure (NASDAQ:NVCR) announces that the final patient has been enrolled in phase 3 pivotal INNOVATE-3 trial evaluating the efficacy of Tumor Treating Fields ((TTFields)) together with paclitaxel for treatment of patients with platinum-resistant ovarian cancer. Following the completion of enrollment, an independent Data Monitoring Committee (DMC) will conduct the pre-specified interim analysis pursuant to the trial protocol. INNOVATE-3 is a randomized, open-label study which was designed to enroll 540 adult patients with recurrent, platinum-resist ovarian cancer. The primary endpoint is overall survival, while secondary endpoints include progression free survival, objective response rate, severity and frequency of adverse events, time to undisputable deterioration in health-related quality of life or death, and quality of life. Final data from the INNOVATE-3 trial is anticipated in 2023. Shares up marginally premarket.

For further details see:

Novocure completes enrollment in late-stage TTFields ovarian cancer study